Covid public health emergencies to end in May, but FDA's EUA authority will continue

Katherine Lewin

News Reporter

The Biden administration announced plans late yesterday to extend the Covid-19 national and public health emergencies until May 11, despite two Republican-led bills that are …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid public health emergencies to end in May, but FDA's EUA authority will continue

Katherine Lewin

News Reporter

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Applied Therapeutics' rare disease drug gets a CRL

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Covid pub­lic health emer­gen­cies to end in May, but FDA's EUA au­thor­i­ty will con­tin­ue

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Covid public health emergencies to end in May, but FDA's EUA authority will continue

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Applied Therapeutics' rare disease drug gets a CRL

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life